Evacetrapib
|
WikiDoc Resources for Evacetrapib |
|
Articles |
|---|
|
Most recent articles on Evacetrapib Most cited articles on Evacetrapib |
|
Media |
|
Powerpoint slides on Evacetrapib |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Evacetrapib at Clinical Trials.gov Clinical Trials on Evacetrapib at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Evacetrapib
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Evacetrapib Discussion groups on Evacetrapib Patient Handouts on Evacetrapib Directions to Hospitals Treating Evacetrapib Risk calculators and risk factors for Evacetrapib
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Evacetrapib |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Overview
Evacetrapib is a drug under development by Eli Lilly & Company (investigational name LY2484595) that inhibits cholesterylester transfer protein, which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease.[1] The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure,[2] which led to excess cardiac events when it was studied.[2] Evacetrapib does not have the same effect.[1] When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile.[3]
Evacetrapib is one of two CETP inhibitors currently being evaluated (the other being anacetrapib).[1] Two other CETP inhibitors (torcetrapib and dalcetrapib) were discontinued during trials due to increased deaths and little identifiable cardiovascular benefit (despite substantial increases in HDL). Some hypothesize that CETP inhibitors may still be useful in the treatment of dyslipidemia, though significant caution is warranted.[2]
References
- ↑ 1.0 1.1 1.2 Cao G, Beyer TP, Zhang Y; et al. (2011). "Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure". J. Lipid Res. 52 (12): 2169–76. doi:10.1194/jlr.M018069. PMID 21957197. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 2.2 Joy T, Hegele RA (2009). "The end of the road for CETP inhibitors after torcetrapib?". Curr. Opin. Cardiol. 24 (4): 364–71. doi:10.1097/HCO.0b013e32832ac166. PMID 19522058. Unknown parameter
|month=ignored (help) - ↑ Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE (2011). "Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol". JAMA. 306 (19): 2099–109. doi:10.1001/jama.2011.1649.